Abstract
MicroRNAs (miRNAs) are endogenously expressed and evolutionarily conserved small non-coding RNAs, which regulate gene expression. Several studies have shown that they are involved in fundamental biological processes, such as proliferation and apoptosis. MicroRNA dysregulation plays an important role in cancer onset and progression where miRs can function as both tumor promoters (oncomiRs) or tumor suppressors by targeting numerous biomolecules that are important in carcinogenesis. MicroRNA molecules are already entering the clinic as diagnostic and prognostic biomarkers for patient stratification and also as therapeutic targets and agents. Their role as biomarkers and therapeutic targets is appealing but several obstacles have as yet limited our ability to translate this potential into a clinical reality. This review provides a comprehensive overview of miRNAs with established functional relevance in cancer. Furthermore, approaches towards therapeutic miRNA-based intervention are discussed. Those include viral or non-viral approaches of miRNA replacement therapy in the case of tumor-suppressing miRNAs and strategies for the inhibition of oncogenic miRNAs.
Current Pharmaceutical Design
Title:microRNAs as Anti-Cancer Therapy
Volume: 20 Issue: 33
Author(s): Michela Garofalo, Gianpiero Di Leva and Carlo M. Croce
Affiliation:
Abstract: MicroRNAs (miRNAs) are endogenously expressed and evolutionarily conserved small non-coding RNAs, which regulate gene expression. Several studies have shown that they are involved in fundamental biological processes, such as proliferation and apoptosis. MicroRNA dysregulation plays an important role in cancer onset and progression where miRs can function as both tumor promoters (oncomiRs) or tumor suppressors by targeting numerous biomolecules that are important in carcinogenesis. MicroRNA molecules are already entering the clinic as diagnostic and prognostic biomarkers for patient stratification and also as therapeutic targets and agents. Their role as biomarkers and therapeutic targets is appealing but several obstacles have as yet limited our ability to translate this potential into a clinical reality. This review provides a comprehensive overview of miRNAs with established functional relevance in cancer. Furthermore, approaches towards therapeutic miRNA-based intervention are discussed. Those include viral or non-viral approaches of miRNA replacement therapy in the case of tumor-suppressing miRNAs and strategies for the inhibition of oncogenic miRNAs.
Export Options
About this article
Cite this article as:
Garofalo Michela, Leva Di Gianpiero and Croce M. Carlo, microRNAs as Anti-Cancer Therapy, Current Pharmaceutical Design 2014; 20 (33) . https://dx.doi.org/10.2174/1381612820666140128211346
DOI https://dx.doi.org/10.2174/1381612820666140128211346 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Altered Glycosylation of Proteins in Cancer: What Is the Potential for New Anti-Tumour Strategies
Anti-Cancer Agents in Medicinal Chemistry Tocilizumab Labeling with 99mTechnetium via HYNIC as a Molecular Diagnostic Agent for Multiple Myeloma
Anti-Cancer Agents in Medicinal Chemistry Inhibitors of Aldo-Keto Reductases AKR1C1-AKR1C4
Current Medicinal Chemistry Bismuth-213 and Actinium-225 – Generator Performance and Evolving Therapeutic Applications of Two Generator-Derived Alpha-Emitting Radioisotopes
Current Radiopharmaceuticals Synthesis of Pyridine and Spiropyridine Derivatives Derived from 2-aminoprop- 1-ene-1,1,3-tricarbonitrile Together with their c-Met Kinase and Antiproliferative Evaluations
Anti-Cancer Agents in Medicinal Chemistry Prediction and Analysis of Hepatocellular Carcinoma Related Genes Using Gene Ontology and KEGG
Current Bioinformatics Prokaryotic Arsenate Reductase Enhances Arsenate Resistance in Mammalian Cells
Recent Patents on Food, Nutrition & Agriculture Molecular Response to Hypericin-Induced Photodamage
Current Medicinal Chemistry ATP-Binding Cassette Efflux Transporters in Human Placenta
Current Pharmaceutical Biotechnology The Adenosine A2b Receptor: Its Role in Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Advances in the Design and Synthesis of c-Met Inhibitors as Anticancer Agents (2014-Present)
Current Medicinal Chemistry Oligonucleotides and G-quadruplex Stabilizers: Targeting Telomeres and Telomerase in Cancer Therapy
Current Pharmaceutical Design DNMT Inhibitors in Cancer, Current Treatments and Future Promising Approach: Inhibition of Specific DNMT-Including Complexes
Epigenetic Diagnosis & Therapy (Discontinued) Thymidine Phosphorylase Over-Expression in Oral Squamous Carcinoma Tissue as a Potential Target of Capecitabine
Letters in Drug Design & Discovery Optimizing Gene Silencing Strategies for Pancreatic Cancer
Current Cancer Therapy Reviews Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer
Mini-Reviews in Medicinal Chemistry Role of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) in Different Disease States: Recent Updates
Current Medicinal Chemistry Dimethylaminoparthenolide, A Water Soluble Parthenolide, Suppresses Lung Tumorigenesis Through Down-Regulating the STAT3 Signaling Pathway
Current Cancer Drug Targets Characterization of Liver- and Cancer-type-Organic Anion Transporting Polypeptide (OATP) 1B3 Messenger RNA Expression in Normal and Cancerous Human Tissues
Drug Metabolism Letters Targeting p73 - a Potential Approach in Cancer Treatment
Current Pharmaceutical Design